Capricor Therapeutics vs Janux Therapeutics
Capricor Therapeutics and Janux Therapeutics are similar in size: $0 and $10.0m of revenue in their latest fiscal years. Janux Therapeutics grew faster (-5.6% against -100.0%). Capricor Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Capricor TherapeuticsCAPR, 2025 | Janux TherapeuticsJANX, 2025 |
|---|---|---|
| Revenue | $0 | $10.0m |
| Revenue growth | -100.0% | -5.6% |
| Net income | −$105m | −$114m |
| Operating margin | — | -1576.7% |
| Net margin | — | -1136.3% |
| Return on equity | -46.6% | -11.5% |
| Free cash flow | −$72.7m | −$83.3m |
| Cash | $288m | $52.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 231 | 109 |
| Market value | $478m | $1.08bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 13 sales | 0 buys, 11 sales |